NCT00168701 - Efficacy and Safety of BG00012 in MS | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

October 1, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Multiple Sclerosis

Interventions

DRUG

BG00012

Trial Locations (42)

1145

Uzsoki Hospital, Budapest

4012

University of Debrecen, Debrecen

6100

Hacettepe Unisersitesi, Ankara

9024

Petz Aladar County Hospital, Győr

34303

Istanbul University, Istanbul

37073

George-August-Universitat Goettigen, Goettigen

40225

Heinrich-Heine-Universitat, Düsseldorf

44791

Bochum am St. Josef-Hospital, Bochum

123182

Moscow

123367

Moscow

127018

Moscow

194044

Saint Petersburg

194291

Saint Petersburg

197022

Saint Petersburg

197376

Saint Petersburg

603076

Veliky Novgorod

630075

Novosibirsk

1153682

Moscow

656 91

Faculty Hospital St. Anne, Bmo

500 05

Faculty Hospital, Hradec Králové

532 03

Hospital of Pardubice, Pardupice

304 60

Faculty Hospital of Plzen, Pilsen

128 02

General Teaching Hospital, Prague

1081 HV

VUMC, Amsterdam

3015 GD

Academic Hospital Rotterdam, Rotterdam

15-276

SamodzielnyPubliczny Szpital Kliniczny, Bialystok

15-420

Niesalezny Zespol Opieki Zdrowognej, Bialystok

85-681

10 Wojskowy Szpital Kliniczny z Poliklinika, Bydgoszcz

80-803

Wojewodzki Szpital Specjalistczny, Gdansk

41-741

Slaskiej Akademii Medycznej, Katowice-Ligota

31-503

Szpital Uniwersytecki w Krakowie, Krakow

90-153

Panstwowy Szpital Kliniczny, Lodz

01-097

Samodzielny Publiczny Centralny Szpital, Warsaw

431 80

MS Centrum, Mölndal

141 86

Karolinska University Hospital, Stockholm

171 76

Karolinska University Hospital, Stockholm

CH 4.31

Kantonsspital Basel, Basel

TR-34390

University of Instanbul, Istanbul

SE1 9RT

Multiple Sclerosis Reseach Clinic, London

WC1N 3BG

Institute of Neurology, London

S10 2JF

Royal Hampshire Hospital, Sheffield

ST4 7LN

University Hospital of North Staffordshire, Stoke-on-Trent